Answers are grounded in this paper and cite their sources.
Catalyst‐free solid phase Hantzsch synthesis of symmetric 4‐(3‐bromo‐4‐hydroxy‐5‐methoxyphenyl)‐2,6‐dimethyl‐3,5‐dicarbethoxy‐1,4‐dihydropyridine (4 a) and 4‐(3‐bromo‐4‐hydroxy‐5‐methoxyphenyl)‐2,6‐dimethyl‐3,5‐dicarbmethoxy‐(4‐nitrophenyl)‐1,4‐dihydropyridine (4 b) was carried out at 400 W under the microwave irradiation. The molecular crystal of both compounds were developed in a suitable solvents and characterized by X‐ray crystallographic method along with other spectroscopic techniques ( viz ., FT‐IR, 1 H & 13 C NMR, LC–MS, and elemental analysis). Single crystal structures of both compounds crystallizes in the orthorhombic and triclinic crystal systems with Cmc2 1 and P 1 space groups consisting a=13.5755(13) Å, b=9.6755(9) Å, c=17.7625(17) Å, α =72.837(2)°, β =88.273(2)°, γ =75.221(2)° and a=8.9877(14) Å, b=11.1543(17) Å, c=12.2365(19) Å, α =90.00°, β =90.00°, γ =90.00° cell parameters, with 0.150 × 0.150 × 0.100 mm 3 and 0.250 × 0.180 × 0.100 mm 3 crystal size respectively. The 1,4‐DHP ring of both compounds have adopted a flattened boat‐type conformation and shows one and four intermolecular hydrogen bonds, respectively.
No takes yet. Share an insight, caveat, or question.
Maru et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: